Amgen To Buy Alantos for $300 Million

Amgen (Nasdaq: AMGN) has agreed to acquire Alantos, a Cambridge, Mass.-based developer of drugs for the treatment of diabetes and inflammatory diseases. The deal is valued at $300 million in cash, and is expected to close next quarter. Alantos has raised nearly $56 million in VC funding since 2000, from firms like Heidelberg Innovation, Earlybird Venture Capital, Oxford Bioscience Partners, SV Life Sciences, Forbion Capital Partners and Ventech. www.amgen.com www.alantos.com